Stock Events

Stock Events

Kyntra Bio 

€5.90
93
+€0.05+0.85% Tuesday 18:17

Statistics

Day High
5.9
Day Low
5.7
52W High
5.9
52W Low
5.7
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10AugExpected
Q1 2026
Next
-3.19
-3.07
-2.94
-2.82
Expected EPS
-2.8177809599999994
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1FG0.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Akebia Therapeutics
AKBA
Mkt Cap248M
Akebia Therapeutics competes in the anemia market, particularly in chronic kidney disease (CKD), similar to FibroGen's roxadustat.
GSK
GSK
Mkt Cap106.31B
GlaxoSmithKline competes with FibroGen in developing treatments for anemia associated with CKD, through their product daprodustat.
Astrazeneca
AZN
Mkt Cap277.22B
AstraZeneca collaborates with FibroGen on roxadustat but also competes in broader therapeutic areas relevant to FibroGen's interests.
AMGEN
AMGN
Mkt Cap191.7B
Amgen, with its portfolio of erythropoiesis-stimulating agents (ESAs) for anemia treatment, competes in the same therapeutic area as FibroGen.
Vertex Pharmaceuticals
VRTX
Mkt Cap112.92B
Vertex Pharmaceuticals is involved in treating cystic fibrosis and other serious diseases, competing with FibroGen's fibrosis research efforts.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.81B
BioMarin Pharmaceutical focuses on rare diseases, including some areas that overlap with FibroGen's interest in rare fibrotic conditions.
Pfizer
PFE
Mkt Cap149.38B
Pfizer has a broad portfolio that includes treatments for fibrosis and cancer, directly competing with several of FibroGen's development programs.
Gilead Sciences
GILD
Mkt Cap155.93B
Gilead Sciences has a strong presence in the treatment of fibrotic diseases, especially with its drug for idiopathic pulmonary fibrosis, competing with FibroGen's fibrosis pipeline.

About

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Show more...
CEO
ISIN
US31572Q8814

Listings

F
DE
1FG0.F
LSE
GB
0IL8.LSE
STU
DE
1FG0.STU
MX
MX
KYNB.MX

0 Comments

Share your thoughts

FAQ

What is Kyntra Bio stock price today?▼
The current price of 1FG0.STU is €5.90 EUR — it has increased by +0.85% in the past 24 hours. Watch Kyntra Bio stock price performance more closely on the chart.
What is Kyntra Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Kyntra Bio stocks are traded under the ticker 1FG0.STU.
Is Kyntra Bio stock price growing?▼
1FG0.STU stock has risen by +2.61% compared to the previous week, the month change is a +0.85% rise, over the last year Kyntra Bio has showed a +3.28% increase.
When is the next Kyntra Bio earnings date?▼
Kyntra Bio is going to release the next earnings report on August 10, 2026.
What were Kyntra Bio earnings last quarter?▼
1FG0.STU earnings for the last quarter are -3.19 EUR per share, whereas the estimation was -2.85 EUR resulting in a -12.07% surprise. The estimated earnings for the next quarter are N/A EUR per share.
In which sector is Kyntra Bio located?▼
Kyntra Bio operates in the Other sector.
When did Kyntra Bio complete a stock split?▼
The last stock split for Kyntra Bio was on June 17, 2025 with a ratio of 1:25.